Found: 6
Select item for more details and to access through your institution.
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 10, p. 5476, doi. 10.3390/ijms23105476
- By:
- Publication type:
- Article
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies.
- Published in:
- EMBO Molecular Medicine, 2020, v. 12, n. 5, p. 1, doi. 10.15252/emmm.201911498
- By:
- Publication type:
- Article
HER3 in cancer: from the bench to the bedside.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2022, v. 41, n. 1, p. 1, doi. 10.1186/s13046-022-02515-x
- By:
- Publication type:
- Article
Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2021, v. 40, n. 1, p. 1, doi. 10.1186/s13046-021-02051-0
- By:
- Publication type:
- Article
Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs.
- Published in:
- Cancers, 2022, v. 14, n. 1, p. 154, doi. 10.3390/cancers14010154
- By:
- Publication type:
- Article
Generation of Antibody-Drug Conjugate Resistant Models.
- Published in:
- Cancers, 2021, v. 13, n. 18, p. 4631, doi. 10.3390/cancers13184631
- By:
- Publication type:
- Article